2024 Videos Archives

Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML

2024-12-18T09:49:08-08:00December 7th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments

2025-06-02T16:15:53-07:00September 23rd, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL

2024-09-25T09:19:32-07:00September 17th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02

2024-09-25T10:07:41-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01

2024-09-25T10:14:27-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

2025-06-10T16:49:59-07:00March 20th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML

Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments

Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML

Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments

Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.